NCT06426680View on ClinicalTrials.gov

A Study of the ILB-3101 in Patients with Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions

Advanced Solid Tumor

Interventions

BIOLOGICAL

ILB-3101

There are eight escalating dose cohorts.

Trial Locations (1)

Unknown

RECRUITING

Fundan University Shanghai Cancer Center, Shanghai

Sponsors

Lead Sponsor

Innolake Biopharm

All Listed Sponsors

lead

Innolake Biopharm

INDUSTRY